We would like to acknowledge the support of the six hundred people listed below who have made donations to the Alameda Post or joined our community as members in the last 12 months. Grants, sponsors, ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...

Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $100.51. The stock’s 50-day moving average is $92.71 and its two-hundred day moving average is $86.32.

The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January 16th.

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to disrupt the pre-exposure prophylaxis (PrEP) market with a twice-yearly ...